Ignite Creation Date:
2024-05-06 @ 5:19 PM
Last Modification Date:
2024-10-26 @ 2:26 PM
Study NCT ID:
NCT05267106
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-06-27
First Post:
2022-02-15
Brief Title:
Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations
Sponsor:
Incyte Corporation
Organization:
Incyte Corporation
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Adult-type Diffuse Gliomas |
| Glioblastoma |
Keywords:
| Name | View |
|---|---|
| circumscribed astrocytic glioma | View |
| glioblastoma | View |
| GBM | View |
| adult-type diffuse gliomas | View |
| gliomas | View |
| oligodendroglioma | View |
| FGFR1-3 Alteration | View |
| FGFR1-3 fusions | View |
| FGFR1-3 rearrangements | View |
| Central nervous system tumor | View |
| isocitrate dehydrogenase | View |
| IDH-mutant astocytoma | View |
| IDH-wild-type GBM | View |
| glioneuronal | View |
| neuronal | View |